Mizuho Medy Co.,Ltd. (TYO:4595)

Japan · Delayed Price · Currency is JPY

1,656.00

+4.00 (0.24%)

Jul 14, 2026, 3:30 PM JST

17.28% (1Y)

Market Cap	31.54B +9.4%
Revenue (ttm)	10.82B -4.6%
Net Income	3.25B -9.2%
EPS	170.56 +2.1%
Shares Out	19.05M
PE Ratio	9.71
Forward PE	n/a
Dividend	100.00 (6.05%)
Ex-Dividend Date	Jun 29, 2026

Volume	45,700
Open	1,664.00
Previous Close	1,652.00
Day's Range	1,656.00 - 1,670.00
52-Week Range	1,402.00 - 1,930.00
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Mizuho Medy

Mizuho Medy Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products, and related scientific and technical information services in Japan. The company offers molecular diagnostic products, such as nucleic acid amplification test products comprising gene analysis instruments and mycoplasma pneumoniae nucleic acid kits. It also provides rapid immunoassay products, including influenza virus antigen test kit; RS virus and human metapneumovirus antigen test kit; streptococcus pneumoniae antigen and legio... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1977

Employees 193

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4595

Full Company Profile

Financial Performance

In 2025, Mizuho Medy's revenue was 11.26 billion, a decrease of -1.48% compared to the previous year's 11.43 billion. Earnings were 3.43 billion, a decrease of -9.22%.

Financial Statements